Physician profile
John Cody Lee
NPI 1134502016
$3,622.29
in general payments reported to CMS, 2019-2025
28 companies · $800 in 2025
The $800 reported for 2025 was more than what 80% of Adult Medicine providers received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $622 · 2020: $475 · 2021: $334 · 2022: $394 · 2023: $324 · 2024: $674 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,766 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.77 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $629.61 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $457.96 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $363.44 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $356.50 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $336.23 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $288.23 | 2019-2024 | Prolia, Evenity, Repatha |
| Abbvie INC. | $222.84 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.28 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $94.85 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $94.35 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $92.86 | 2021-2025 | Rexulti |
| Dynavax Technologies Corporation | $66.56 | 2022-2025 | Heplisav-B |
| Astellas Pharma US INC | $66.34 | 2024-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $60.93 | 2019-2023 | Trintellix |
| Novartis Pharmaceuticals Corporation | $44.92 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $35.97 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $30.15 | 2024-2025 | Caplyta |
| Allergan, INC. | $29.99 | 2019 | |
| Nestle Healthcare Nutrition INC. | $22.10 | 2021 | |
| Lundbeck LLC | $21.15 | 2025 | Rexulti |
| Axsome Therapeutics, INC. | $21.15 | 2025 | Auvelity |
| Esperion Therapeutics, INC. | $18.24 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.74 | 2025 | |
| Inspire Medical Systems, INC. | $17.16 | 2025 | Inspire |
| Alexion Pharmaceuticals, INC. | $16.16 | 2023 | Strensiq |
| Eisai INC. | $15.20 | 2020 | |
| Sanofi-Aventis U.S. LLC | $14.76 | 2022 | |
| Arbor Pharmaceuticals, INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.